Intermittent Porphyria
📧 Sign up to get email alerts when something new happens for Intermittent Porphyria.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment [NA]
A clinical trial is studying the use of a carbohydrate-rich diet to treat acute intermittent porphyria and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Panhematin for Prevention of Acute Attacks of Porphyria [Phase 2]
Phase 2 study of Panhematin (hemin) to prevent acute attacks in porphyrias was terminated, with results posted on 2026-01-30.
-
CLINICAL_TRIALS research · 2025-08-28Clinical Trial Update: Identification of Acute Intermittent Porphyria Modifying Genes
A clinical trial is investigating genetic modifiers that influence Acute Intermittent Porphyria, currently recruiting with Icahn School of M…
-
CLINICAL_TRIALS research · 2025-04-18Clinical Trial Update: Acute Porphyria Biomarkers for Disease Activity
An ongoing clinical trial from The University of Texas Medical Branch evaluating biomarkers for disease activity in porphyrias. The study is…
-
CLINICAL_TRIALS research · 2024-05-09Clinical Trial Update: Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
A ClinicalTrials.gov update for Acute Intermittent Porphyria examining dental health, diet, inflammation, and biomarkers; the study is curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) [Phase 1, Phase 2]
A study evaluating long-term safety and clinical activity of givosiran (ALN-AS1) in patients with acute intermittent porphyria has completed…
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) [Phase 3]
Phase 3 trial evaluating givosiran (ALN-AS1) for acute hepatic porphyrias has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
A terminated Alnylam-sponsored study (INSIGHT-AHP) sought to characterize the prevalence of acute hepatic porphyrias among patients with cli…
-
CLINICAL_TRIALS trial_result · 2018-06-14Clinical Trial Update: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) [Phase 1]
This clinical trial update reports the completion of a Phase 1 study of givosiran (ALN-AS1) in patients with Acute Intermittent Porphyria.
-
CLINICAL_TRIALS trial_result · 2018-03-09Clinical Trial Update: Porphozym in the Treatment of Acute Attacks in AIP [Phase 2, Phase 3]
Porphozym is studied in a Phase 2/Phase 3 trial for acute attacks in Acute Intermittent Porphyria. The trial status is completed.
-
CLINICAL_TRIALS trial_result · 2017-10-13Clinical Trial Update: Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride [Phase 1]
Phase 1 study assessing intra-subject variability in the bioavailability of chlorpromazine hydrochloride. The study is completed and results…
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria [Phase 1]
A Phase I gene therapy trial using the rAAV2/5-PBGD vector for acute intermittent porphyria has completed.
-
CLINICAL_TRIALS research · 2014-03-12Clinical Trial Update: Observational Study of Acute Intermittent Porphyria Patients
The observational study of Acute Intermittent Porphyria patients sponsored by Digna Biotech S.L. has completed.